Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer

Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer

(2021) Ali Ghoochani et al.   CANCER RESEARCH

Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

(2021) Claire M. Patterson et al.   Communications Biology

Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

(2021) Yi Liang et al.   CLINICAL CANCER RESEARCH

Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells

(2021) Ryan Kolb et al.   Nature Communications

Signaling Pathways That Control Apoptosis in Prostate Cancer

(2021) Amaal Ali et al.   Cancers

It's time to die: BH3 mimetics in solid tumors

(2021) Sarah Kehr et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives

(2021) Shirin Hafezi et al.   Cancers

A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer

(2021) Daniel Westaby et al.   Annual Review of Pharmacology and Toxicology

A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results.

(2021) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

(2021) Oliver Sartor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutics Targeting the Core Apoptotic Machinery

(2021) Claudia Hamilton et al.   Cancers

Review of Venetoclax in CLL, AML and Multiple Myeloma

(2021) Masa Lasica et al.   Journal of Personalized Medicine

A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma

(2021) Surein Arulananda et al.   Cell Death Discovery

Evasion of cell death: A contributory factor in prostate cancer development and treatment resistance

(2021) Kirsteen J. Campbell et al.   CANCER LETTERS

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

MARCH5-dependent degradation of MCL1/NOXA complexes defines susceptibility to antimitotic drug treatment

(2020) Manuel D. Haschka et al.   CELL DEATH AND DIFFERENTIATION

Overall survival and second primary malignancies in men with metastatic prostate cancer

(2020) Juha Mehtälä et al.   PLoS One

Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial

(2020) Andrew Henry Wei et al.   BLOOD

Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor positive breast cancer

(2020) James R Whittle et al.   CLINICAL CANCER RESEARCH

First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in U.S. patients with metastatic solid tumors.

(2020) Nehal J. Lakhani et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting apoptosis in cancer therapy

(2020) Benedito A. Carneiro et al.   Nature Reviews Clinical Oncology

Robust autoactivation for apoptosis by BAK but not BAX highlights BAK as an important therapeutic target

(2020) Sweta Iyer et al.   Cell Death & Disease

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression

(2020) Yuto Yasuda et al.   Cell Death & Disease

Discovery of A-1331852, a First-in-Class, Potent and Orally-Bioavailable BCL-XL Inhibitor

(2020) Le Wang et al.   ACS Medicinal Chemistry Letters

MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation

(2020) Seiji Arai et al.   eLife

Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation

(2020) Hua Xu et al.   Cancers

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

(2020) Yonghan He et al.   Journal of Hematology & Oncology

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells

(2020) Nabanita Mukherjee et al.   Cell Death & Disease

LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)

(2020) J.S. de Bono et al.   ANNALS OF ONCOLOGY

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

(2020) Wassim Abida et al.   JOURNAL OF CLINICAL ONCOLOGY

MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically

(2020) Enkhtsetseg Munkhbaatar et al.   Nature Communications

Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity — United States, 2001–2017

(2020) David A. Siegel et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Up-Regulation of RIP3 Alleviates Prostate Cancer Progression by Activation of RIP3/MLKL Signaling Pathway and Induction of Necroptosis

(2020) Ke-jie Wang et al.   Frontiers in Oncology

MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents

(2020) Arnold Bolomsky et al.   Journal of Hematology & Oncology

Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment

(2020) Vicenç Ruiz de Porras et al.   EUROPEAN UROLOGY

Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins

(2019) Rumani Singh et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1

(2019) Thomas J. Ow et al.   Oncotarget

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer

(2019) Nicholas G. Nickols et al.   PROSTATE CANCER AND PROSTATIC DISEASES

A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer

(2019) Shanshan Bai et al.   ONCOGENE

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

(2019) Andrew W. Roberts et al.   BLOOD

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

(2019) Karim Fizazi et al.   LANCET ONCOLOGY

Genomic correlates of clinical outcome in advanced prostate cancer

(2019) Wassim Abida et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival

(2019) Erinna F. Lee et al.   Cell Death & Disease

The TP53 Apoptotic Network is a Primary Mediator of Resistance to BCL2 inhibition in AML Cells

(2019) Tamilla Nechiporuk et al.   Cancer Discovery

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

(2019) Andrew J. Armstrong et al.   JOURNAL OF CLINICAL ONCOLOGY

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

(2019) Kirsten Fischer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

(2019) Ian D. Davis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

(2019) Kim N. Chi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration‐resistant prostate cancer cells to enzalutamide

(2019) Amanda B. Pilling et al.   PROSTATE

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

(2019) Romain Guièze et al.   CANCER CELL

BH3-only proteins target BCL-xL/MCL-1, not BAX/BAK, to initiate apoptosis

(2019) Kai Huang et al.   CELL RESEARCH

A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma

(2019) Andrew Spencer et al.   Clinical Lymphoma Myeloma & Leukemia

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

(2019) Matthew J. Sale et al.   Nature Communications

Drivers of AR indifferent anti-androgen resistance in prostate cancer cells

(2019) Florian Handle et al.   Scientific Reports

Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer

(2019) Alexandra N. Corella et al.   CLINICAL CANCER RESEARCH

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

(2019) Sajid Khan et al.   NATURE MEDICINE

Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells

(2018) Mohamed Rahmani et al.   CANCER RESEARCH

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018

(2018) Lorenzo Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis

(2018) Seiji Arai et al.   CLINICAL CANCER RESEARCH

Metastatic Prostate Cancer

(2018) Oliver Sartor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

(2018) John F. Seymour et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition

(2018) Clare E. Weeden et al.   ONCOGENE

Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells

(2018) Federico Lucantoni et al.   Cell Death & Disease

Targeting BCL-2 regulated apoptosis in cancer

(2018) Kirsteen J. Campbell et al.   Open Biology

Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies

(2018) Brandon Bumbaca et al.   Acta Pharmaceutica Sinica B

BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL

(2018) Georgia Greaves et al.   CELL DEATH AND DIFFERENTIATION

Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity

(2018) Ryan S. Soderquist et al.   Nature Communications

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses

(2018) Qiuhui Li et al.   Nature Communications

AMG 176, a Selective MCL1 Inhibitor, is Effective in Hematological Cancer Models Alone and in Combination with Established Therapies

(2018) Sean Caenepeel et al.   Cancer Discovery

Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer

(2018) Sonia Vallet et al.   BREAST CANCER RESEARCH AND TREATMENT

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

(2018) Razvan Cristescu et al.   SCIENCE

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

(2018) Adriana E. Tron et al.   Nature Communications

Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia

(2018) Piers Blombery et al.   Cancer Discovery

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

(2017) Tomasz M. Beer et al.   EUROPEAN UROLOGY

Implications of Bcl-2 and its interplay with other molecules and signaling pathways in prostate cancer progression

(2017) Ju-Ha Kim et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

(2017) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

(2017) Avi Ashkenazi et al.   NATURE REVIEWS DRUG DISCOVERY

Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells

(2017) Jane Levesley et al.   NEURO-ONCOLOGY

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

(2017) Nicholas D. James et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer

(2017) Ping Mu et al.   SCIENCE

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer

(2017) Delphine Merino et al.   Science Translational Medicine

BCL-XL overexpression promotes tumor progression-associated properties

(2017) Daniela Trisciuoglio et al.   Cell Death & Disease

Emerging Variants of Castration-Resistant Prostate Cancer

(2017) Panagiotis J. Vlachostergios et al.   Current Oncology Reports

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1

(2016) J.-N. Gong et al.   BLOOD

PTBP1 modulation of MCL1 expression regulates cellular apoptosis induced by antitubulin chemotherapeutics

(2016) J Cui et al.   CELL DEATH AND DIFFERENTIATION

Regulated cell death and adaptive stress responses

(2016) Lorenzo Galluzzi et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

A Phase II Study of AT-101 to Overcome Bcl-2–Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer

(2016) Mark N. Stein et al.   Clinical Genitourinary Cancer

Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis

(2016) Marcello Tucci et al.   EUROPEAN UROLOGY

Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane

(2016) Katelyn L. O'Neill et al.   GENES & DEVELOPMENT

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

(2016) Nicholas D James et al.   LANCET

Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-X L Inhibition

(2016) Wenying Ren et al.   MOLECULAR CANCER RESEARCH

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

(2016) E. A. Punnoose et al.   MOLECULAR CANCER THERAPEUTICS

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells

(2016) Mohammed Najim Abed et al.   Journal of Ovarian Research

Mitochondrial apoptosis: killing cancer using the enemy within

(2015) J Lopez et al.   BRITISH JOURNAL OF CANCER

Integrative Clinical Genomics of Advanced Prostate Cancer

(2015) Dan Robinson et al.   CELL

The Molecular Taxonomy of Primary Prostate Cancer

(2015) Adam Abeshouse et al.   CELL

Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma

(2015) M. Klanova et al.   CLINICAL CANCER RESEARCH

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

(2015) Charles J Ryan et al.   LANCET ONCOLOGY

GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells

(2015) Styliani Karanika et al.   Molecular Cancer

Limited Mitochondrial Permeabilization Causes DNA Damage and Genomic Instability in the Absence of Cell Death

(2015) Gabriel Ichim et al.   MOLECULAR CELL

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

(2015) J D Leverson et al.   Cell Death & Disease

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin

(2015) Zuzanna Baranski et al.   Oncotarget

New dimension in therapeutic targeting of BCL-2 family proteins

(2015) Samaher Besbes et al.   Oncotarget

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy

(2015) Frédéric R. Santer et al.   Oncotarget

Combining Paclitaxel with ABT-263 Has a Synergistic Effect on Paclitaxel Resistant Prostate Cancer Cells

(2015) Chihuei Wang et al.   PLoS One

Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition

(2015) Hiroki Tamaki et al.   Oncotarget

PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells

(2015) Martin Puhr et al.   Oncotarget

Sabutoclax, a Mcl-1 Antagonist, Inhibits Tumorigenesis in Transgenic Mouse and Human Xenograft Models of Prostate Cancer

(2015) Roger S. Jackson et al.   NEOPLASIA

MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice

(2014) S. Grabow et al.   BLOOD

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015

(2014) L Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Small cell carcinoma of the prostate

(2014) Rosa Nadal et al.   Nature Reviews Urology

A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia

(2014) Aaron D. Schimmer et al.   PLoS One

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

(2014) Zhi-Fu Tao et al.   ACS Medicinal Chemistry Letters

Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure

(2013) R. L. Thomas et al.   GENES & DEVELOPMENT

Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction

(2013) X. Wang et al.   GENES & DEVELOPMENT

Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases

(2013) Canan Akfirat et al.   JOURNAL OF PATHOLOGY

BH3 profiling in whole cells by fluorimeter or FACS

(2013) Jeremy Ryan et al.   METHODS

Structure-guided design of a selective BCL-XL inhibitor

(2013) Guillaume Lessene et al.   Nature Chemical Biology

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

(2013) Peter E. Czabotar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

(2013) C. Parker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells

(2013) Dominick G. A. Burton et al.   PLoS One

Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism

(2013) Qiong Liu et al.   PROSTATE

Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer

(2013) Javier Guerrero et al.   PROSTATE

Evading apoptosis in cancer

(2013) Kaleigh Fernald et al.   TRENDS IN CELL BIOLOGY

Inhibitor of Apoptosis (IAP) Proteins-Modulators of Cell Death and Inflammation

(2013) J. Silke et al.   Cold Spring Harbor Perspectives in Biology

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

(2013) R. Pan et al.   Cancer Discovery

ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells

(2013) Ricardo Parrondo et al.   PeerJ

ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment

(2012) N. J. Clegg et al.   CANCER RESEARCH

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

(2012) S. P. Glaser et al.   GENES & DEVELOPMENT

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

(2012) Karim Fizazi et al.   LANCET ONCOLOGY

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Delving deeper: MCL-1's contributions to normal and cancer biology

(2012) Rhonda M. Perciavalle et al.   TRENDS IN CELL BIOLOGY

Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer

(2011) G. Sonpavde et al.   ANNALS OF ONCOLOGY

Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells

(2011) A. A. Morales et al.   BLOOD

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

(2011) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction

(2011) Hiroyuki Inuzuka et al.   NATURE

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

(2011) T. N. Chonghaile et al.   SCIENCE

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

(2011) H. Beltran et al.   Cancer Discovery

To Die or to Survive, a Fatal Question for the Destiny of Prostate Cancer Cells after Androgen Deprivation Therapy

(2011) Kai-Xin Zhang et al.   Cancers

An Optically Pure Apogossypolone Derivative as Potent Pan-Active Inhibitor of Anti-Apoptotic Bcl-2 Family Proteins

(2011) Jun Wei et al.   Frontiers in Oncology

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bcl-2 as a Predictive Factor for Biochemical Recurrence after Radical Prostatectomy: An Interim Analysis

(2010) In-Chang Cho et al.   Cancer Research and Treatment

An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer

(2009) G. Liu et al.   CLINICAL CANCER RESEARCH

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

(2009) Martin Schwickart et al.   NATURE

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model

(2008) Carolyn Waugh Kinkade et al.   JOURNAL OF CLINICAL INVESTIGATION